DLX6 and colorectal carcinoma: External validation based on additional 379 CRC patients (1.86 years of median follow-up time, 86 overall deaths) from the TCGA database confirmed the poorer prognosis with hypermethylated DLX6-AS1 (P = 0.007), and the HR (95%CI) for overall survival (OS) by multivariate Cox proportional hazards regression model was 1.64 (1.02-2.64, P = 0.042) (Supplementary Figure S10).